Condition
Fibroblast
Total Trials
4
Recruiting
1
Active
1
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 4 trials
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Not Yet Recruiting2
Unknown1
Recruiting1
Clinical Trials (4)
Showing 4 of 4 trials
NCT07682636Recruiting
Keloid Pathogenesis And Fibroblast Activation Study
NCT07669636Not Yet Recruiting
Effects of Chlorhexidine on Human Gingival Fibroblasts
NCT06911476Not Yet Recruiting
From Inflammation to Remodelling Towards Personalized Diagnosis in Post-acute Sequelae of COVID-19
NCT01154842UnknownPrimary
Fibroblast Growth Factor-23 (FGF-23) is Independently Associated With Left Ventricular Mass Index (LVMI) and Myocardial Performance Index (MPI) in Haemodialysis Patients
Showing all 4 trials